SCHEMBL3097004

SCHEMBL3097004

CCOC(=O)C(Cc1ccncc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.50
MMP8 P22894 1/20 0.48
PKM P14618 1/20 0.47
GAA P10253 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TP53 P04637 1/20 0.44
RAPGEF3 O95398 1/20 0.43
F2 P00734 2/20 0.43
POLB P06746 2/20 0.43
KAT6A Q92794 2/20 0.43
TSHR P16473 1/20 0.42
BACE1 P56817 1/20 0.42
IDO1 P14902 1/20 0.42
HIF1A Q16665 1/20 0.41
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091388 0.91 MMP8 (0.58) LARS1MMP8PKMGAAALDH1A1
SCHEMBL3093748 0.89 LARS1 (0.54) LARS1MMP8GAAALDH1A1MEN1
SCHEMBL3093170 0.88 ALDH1A1 (0.54) LARS1MMP8GAAALDH1A1KMT2A
SCHEMBL3100450 0.88 LARS1 (0.53) LARS1MMP8PKMGAAALDH1A1
SCHEMBL3097275 0.88 MMP8 (0.51) LARS1MMP8PKMGAAALDH1A1
SCHEMBL3090769 0.87 LARS1 (0.53) LARS1GAAALDH1A1RAPGEF3F2
SCHEMBL3090763 0.86 LARS1 (0.52) LARS1GAAALDH1A1RAPGEF3F2
SCHEMBL3103795 0.85 LARS1 (0.47) LARS1MMP8GAAALDH1A1TP53
SCHEMBL3085503 0.85 LARS1 (0.47) LARS1MMP8GAAALDH1A1KMT2A
SCHEMBL3090766 0.85 LARS1 (0.51) LARS1GAAALDH1A1RAPGEF3F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885MMP8 3060/4885PKM 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.